News | Heart Failure | December 22, 2017

ACC Issues New Guidance to Optimize Heart Failure Treatment

Document addresses ten issues regarding heart failure with reduced ejection fraction

ACC Issues New Guidance to Optimize Heart Failure Treatment

December 22, 2017 — To help streamline treatment of patients with heart failure and ensure the best possible patient outcomes, the American College of Cardiology published an expert consensus decision pathway for the optimization of treatment for patients with heart failure with reduced ejection fraction.

“Heart failure care has become increasingly complex with multiple medications that are evidence-based, several choices of devices and an array of process of care interventions,” said Clyde W. Yancy, M.D., MSc, MACC, chair of the writing committee. “A practical approach is needed to optimize care and improve outcomes.”

This document complements the 2017 ACC/AHA/HFSA Focused Update of the 2013 ACC/AHA Guideline for the Management of Heart Failure by addressing new medical therapies, prevention and comorbidities relevant to heart failure with reduced ejection fraction for which data are available. Despite new guideline statements, information voids exist, and a practical, consensus approach is needed for areas that have incomplete evidence. The writing committee identified and addressed ten pivotal issues that remain unresolved in the guidelines:

  1. How to initiate, add or switch therapy to new evidence-based guideline-directed treatments for heart failure with reduced ejection fraction.
  2. How to achieve optimal therapy given multiple drugs for heart failure including augmented clinical assessment that may trigger additional changes in guideline-directed therapy (e.g., imaging data, biomarkers and filling pressures).
  3. When to refer to a heart failure specialist.
  4. How to address challenges of care coordination.
  5. How to improve adherence.
  6. What is needed in specific patient cohorts: African Americans, the frail and older adults.
  7. How to manage your patients’ cost of care for heart failure.
  8. How to manage the increasing complexity of heart failure.
  9. How to manage common comorbidities.
  10. How to integrate palliative care and transition to hospice care.

“There has been a challenge with implementation of guidelines across the board,” Yancy said. “This document is a major step toward deploying aspects of implementation science as a means to improve adherence to evidence-based guideline-directed therapy.”

Each member of the writing committee—representative of all stakeholders—facilitated a separate survey with their own constituency to make certain that all needs were acknowledged and addressed, if possible. This treatment document is among the first of its kind to be open to public comment during peer review. Those public comments were given the same considerations in the revisions of this document as formal peer review. According to the writing committee, this public-comments process may be a new way of developing documents, in the hope that it will allow consensus to follow much more quickly than before.

The 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction will be published online in the Journal of the American College of Cardiology.

For more information: www.acc.org

 

Related Heart Failure Content

First Transcatheter Implant for Diastolic Heart Failure Successful

Surgery Could Reduce Frailty in Adults With Heart Failure

FDA Approves Pacemaker to Treat Central Sleep Apnea

Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure

VIDEO: Predicting Right Ventricular Failure Using 2-D, 3-D and Strain Echo

Medtronic HeartWare HVAD System Approved for Destination Therapy

Related Content

Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Antithrombin Drug Ineffective in Heart Failure With Sinus Rhythm and Coronary Disease
News | Heart Failure | September 07, 2018
The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction...
Tafamidis Improves Survival in Rare Heart Condition
News | Heart Failure | September 06, 2018
Tafamidis is the first treatment to improve survival and reduce hospitalizations in a rare heart condition called...
New Target for Treating Heart Failure Identified by Penn Medicine Researchers

Microtubules in heart cells from a healthy patient (left) and from a patient with heart failure. The dense network of detyrosinated microtubules impedes the motion of the failing heart cell during the heart beat. Credit: Ben Prosser lab, Perelman School of Medicine, University of Pennsylvania

News | Heart Failure | June 25, 2018
New research finds changes in cellular struts called microtubules (MT) can affect the stiffness of diseased human heart...
Gencaro Does Not Reduce Atrial Fibrillation Risk in Heart Failure Patients
News | Heart Failure | May 30, 2018
Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European...
Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Image courtesy of Impulse Dynamics

News | Heart Failure | May 18, 2018
In a new study, cardiac contractility modulation (CCM) therapy was confirmed to significantly improve exercise...
V-Wave Closes $70M Financing to Support Pivotal Study of Heart Failure Therapy
News | Heart Failure | May 16, 2018
Israel-based V-Wave Ltd. recently closed a $70 million Series C financing for its proprietary, minimally invasive...
News | Heart Failure | May 14, 2018
Ancora Heart Inc. announced the expansion of the company’s U.S. feasibility study to evaluate the investigational...
Protein Clumping May Contribute to Heart Failure Development

A PET scan detects clumping proteins in rat hearts (top). The enlarged heart (right) is one with heart failure. Other PET scans showing blood flow in the rat hearts (bottom) show that the protein clumps aren't due to circulation problems. Image courtesy of Circulation Research, May 11, 2018.

News | Heart Failure | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Overlay Init